Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.
NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...
Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...
A drug pricing expert reveals the shocking cost disparity of a life-saving spinal muscular atrophy drug in India, priced at ...
No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...
Pharmacy Benefit Managers are the middlemen who manage virtually all prescriptions written in the U.S. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities ...
The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...
Hawaii has another opportunity to seek damages against the country’s three largest pharmacy benefit managers over alleged ...
FTC sues drug middlemen for allegedly inflating insulin prices Pfizer says drug for deadly cancer condition that causes weight loss shows positive trial data Gilead says its twice-yearly shot cut ...
14d
Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback